128 related articles for article (PubMed ID: 36965291)
1. Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Musacchio L; Turinetto M; Arenare L; Bartoletti M; Califano D; Tuninetti V; Marchetti C; Cormio G; Loizzi V; Pisano C; Salutari V; Valabrega G; Priolo D; Cecere SC; Ventriglia J; Raspagliesi F; Perrone F; Fagotti A; Lorusso D; Scambia G; Pignata S
Gynecol Oncol; 2023 May; 172():72-77. PubMed ID: 36965291
[TBL] [Abstract][Full Text] [Related]
2. Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
Fuh KC; Secord AA; Bevis KS; Huh W; ElNaggar A; Blansit K; Previs R; Tillmanns T; Kapp DS; Chan JK
Gynecol Oncol; 2015 Dec; 139(3):413-8. PubMed ID: 26144600
[TBL] [Abstract][Full Text] [Related]
3. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Backes FJ; Richardson DL; McCann GA; Smith B; Salani R; Eisenhauer EL; Fowler JM; Copeland LJ; Cohn DE; O'Malley DM
Int J Gynecol Cancer; 2013 Jun; 23(5):833-8. PubMed ID: 23640292
[TBL] [Abstract][Full Text] [Related]
4. Low-dose (7.5 mg/kg) bevacizumab may be a viable option in recurrent ovarian cancer: A retrospective study.
Demirkiran A; Eryilmaz MK; Karaagac M; Araz M; Korkmaz M; Koçak MZ; Artac M
J Cancer Res Ther; 2023; 19(3):595-600. PubMed ID: 37470581
[TBL] [Abstract][Full Text] [Related]
5. Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea.
Kim SI; Kim JH; Noh JJ; Kim SH; Kim TE; Kim K; Park JY; Lim MC; Lee JW; Kim JW
Gynecol Oncol; 2022 Sep; 166(3):444-452. PubMed ID: 35863991
[TBL] [Abstract][Full Text] [Related]
6. Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience.
Fukuda T; Noda T; Uchikura E; Awazu Y; Tasaka R; Imai K; Yamauchi M; Ichimura T; Yasui T; Sumi T
Anticancer Res; 2023 Jul; 43(7):3097-3105. PubMed ID: 37351971
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
Manning-Geist BL; Kahn RM; Nemirovsky D; Girshman J; Laibangyang A; Gordhandas S; Iasonos A; Chui MH; Long Roche K; Zivanovic O; Chi DS; Aghajanian C; Grisham RN
Cancer; 2023 Jul; 129(13):2004-2012. PubMed ID: 36951509
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Bevacizumab Combined with Albumin-Bound Paclitaxel in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer.
Liu B; An R; Yu J
J BUON; 2019; 24(6):2303-2309. PubMed ID: 31983098
[TBL] [Abstract][Full Text] [Related]
9. Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?
McCann GA; Smith B; Backes FJ; Rath K; Chacko S; Salani R; Eisenhauer E; Fowler JM; Cohn DE; O'Malley DM
Gynecol Oncol; 2012 Nov; 127(2):362-6. PubMed ID: 22885866
[TBL] [Abstract][Full Text] [Related]
10. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
[TBL] [Abstract][Full Text] [Related]
12. Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis.
Takasaki K; Miyamoto M; Takano M; Soyama H; Aoyama T; Matsuura H; Kato K; Sakamoto T; Kuwahara M; Iwahashi H; Ishibashi H; Yoshikawa T; Furuya K
Cancer Chemother Pharmacol; 2018 May; 81(5):809-814. PubMed ID: 29500481
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy of oral cyclophosphamide and bevacizumab for patients with recurrent ovarian and peritoneal cancer.
Goto M; Tsubamoto H; Isono-Taniguchi R; Takimoto Y; Tashima L; Hori K; Ito K
Medicine (Baltimore); 2023 Feb; 102(8):e32880. PubMed ID: 36827071
[TBL] [Abstract][Full Text] [Related]
14. Recurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers.
Dao MD; Alwan LM; Gray HJ; Tamimi HK; Goff BA; Liao JB
Gynecol Oncol; 2013 Aug; 130(2):295-9. PubMed ID: 23632207
[TBL] [Abstract][Full Text] [Related]
15. Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Burger RA; Brady MF; Rhee J; Sovak MA; Kong G; Nguyen HP; Bookman MA
Gynecol Oncol; 2013 Oct; 131(1):21-6. PubMed ID: 23906656
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of survival outcomes between bevacizumab and olaparib in
Kim SI; Lee JW; Kim K; Lee M; Yoo J; Choi MC; Hwangbo S; Kwak YH; Lee JM; Shin SJ; Shim SH; Kim MK
J Gynecol Oncol; 2021 Nov; 32(6):e90. PubMed ID: 34431258
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
[TBL] [Abstract][Full Text] [Related]
18. Impact of Adding Bevacizumab to Paclitaxel + Carboplatin for Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Propensity Score Matching Analysis.
Hirasawa T; Machida H; Iida T; Ikeda M; Shida M; Mikami M
Tokai J Exp Clin Med; 2018 Sep; 43(3):85-89. PubMed ID: 30191541
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
Chen RL; Chen HJ; Jiang BY; Zhang XC; Zhou Q; Tu HY; Zhong WZ; Wu YL; Yang JJ
Clin Transl Oncol; 2018 Feb; 20(2):243-252. PubMed ID: 28702789
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
Pujol JL; Lavole A; Quoix E; Molinier O; Souquet PJ; Barlesi F; Le Caer H; Moro-Sibilot D; Fournel P; Oster JP; Chatellain P; Barre P; Jeannin G; Mourlanette P; Derollez M; Herman D; Renault A; Dayen C; Lamy PJ; Langlais A; Morin F; Zalcman G;
Ann Oncol; 2015 May; 26(5):908-914. PubMed ID: 25688059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]